ClinicalTrials.gg
CompletedNCT04249362DUARTUpdated Jan 10, 2025Results posted

Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy

A Phase 2 interventional study of Durvalumab in Non-small Cell Lung Cancer, sponsored by AstraZeneca. Completed at 35 sites in 6 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-01-10.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Non-randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung — 16 open to participants now, 37 under way, 11 of them phase 3. durvalumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
35th of 94
102 · median 74
Started
2020
with 13 others
Phase 2
58 of 94
11 open now
Registered
55th of 94
by date
Lead sponsor
25 of 94
AstraZeneca

Among the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, this one is the 35th largest by enrollment, is one of 14 that started in 2020, is one of 58 in phase 2, and was the 55th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

16 of the 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About durvalumab

durvalumab: first FDA approval 2017 (IMFINZI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies testing durvalumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who are deemed to be ineligible for chemotherapy per Investigator assessment. Patients will be enrolled into 2 cohorts according to radiotherapy pretreatment dose (Cohort A: standard radiation therapy [60 gray (Gy) ± 10% or hypofractionated bioequivalent dose (BED)]; Cohort B: palliative radiation therapy [40 to \< 54 Gy or hypofractionated BED])

Read the detailed description

This is a Phase II open-label, single-arm, multicenter, international study to evaluate the clinical activity of durvalumab in patients with Stage III unresectable NSCLC who have an Eastern Cooperative Oncology Group (ECOG) PS of 0 to 2 and who were treated with radiotherapy but are ineligible for chemotherapy. Patients will be enrolled into 2 cohorts according to the dose of radiotherapy received prior to study entry (Cohort A: Standard Radiotherapy [60 Gy ± 10% or hypofractionated BED]; Cohort B: Palliative Radiotherapy [40 to \< 54 Gy or hypofractionated BED]). Patients must not have progressed following radiation therapy, and radiation therapy must be completed within 6 weeks (42 days) prior to first study drug administration. The last dose of radiation therapy is defined as the day of the last radiation treatment session. All patients will receive 1500 mg durvalumab via IV infusion every 4 weeks (q4w) for up to a maximum of 12 months (up to 13 doses/cycles)

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Radiation therapy
  • Phase II
  • Palliative Radiotherapy
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving signed .
  2. Age ≥ 18 years at study entry.
  3. or cytologically documented NSCLC with locally-advanced, unresectable Stage III disease.
  4. Deemed ineligible for chemotherapy per Investigator assessment.
  5. Receipt of radiation therapy that was completed within 42 days prior to first study drug administration.
  6. Must have received a total dose of radiation of 40 to 66 Gy (standard or hypofractionated BED).
  7. Must not have progressed following radiation therapy, as per Investigator assessed 1.1 criteria: a) Patients with and/or nonmeasurable and/or no evidence of disease assessed at baseline by computed tomography /magnetic resonance imaging will be eligible for this study. b) Prior irradiated lesions may be considered measurable and selected as target lesions (TLs) providing they fulfill the other criteria for measurability.
  8. World Health Organization/ performance status of ≤2.
  9. No prior exposure to immune-mediated therapy including, but not limited to, , anti-PD-1, anti-PD-L1, and antiprogrammed cell death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
  10. Patients must have adequate organ and marrow function as defined below:

    • ≥ 9.0 g/dL
    • ≥ 1.0 × 109 /L
    • count ≥ 75 × 109/L
    • Serum ≤ 1.5 × the (ULN). This will not apply to patients with confirmed Gilbert's syndrome.
    • and aspartate aminotransferase ≤ 2.5 × ULN
    • Measured > 30 mL/min or calculated CL > 30 mL/min as determined by Cockcroft-Gault
  11. of greater than 12 weeks.
  12. Body weight greater than 30 kg at study entry and at first study drug administration

Exclusion criteria

Exclusion Criteria:

  1. Patients with locally-advanced NSCLC whose disease has progressed following radiation therapy.
  2. Mixed small cell lung cancer and NSCLC histology.
  3. History of allogeneic organ transplantation.
  4. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative, systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome).
  5. Uncontrolled intercurrent illness (e.g., ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris)
  6. History of another primary except for (a) malignancy treated with curative intent and with no known active disease ≥ 5 years before the first study drug administration, (b) adequately treated nonmelanoma skin cancer or lentigo maligna without evidence of disease, and c) treated carcinoma in situ without evidence of disease.
  7. History of
  8. History of active primary immunodeficiency
  9. Active infection including tuberculosis, , , or
  10. Any unresolved toxicity Grade ≥ 2 from previous anticancer therapy with the exception of alopecia, vitiligo, lymphopenia, and the laboratory values defined in the inclusion criteria
  11. Known allergy or to any of the study drugs or any of the study drug .
  12. Receipt of within 30 days prior to the first dose of durvalumab
  13. Major surgical procedure (as defined by the Investigator) within 28 days prior to the first dose of durvalumab.
  14. Current or prior use of medication within 14 days before the first dose of durvalumab.
  15. Participation in another clinical study with an IP administered in the last 4 weeks.
  16. Concurrent enrollment in another clinical study, unless it is an observational (noninterventional) clinical study or during the follow-up period of an interventional study
  17. Prior randomization or treatment in a previous durvalumab clinical study regardless of treatment arm assignment
  18. Patients who refuse chemotherapy by their own decision.
  19. Involvement in the planning and/or conduct of the study
  20. Female patients who are pregnant or breastfeeding or male or female patients of who are not willing to employ effective .
  21. Judgment by the Investigator that the patient should not participate in the study
  22. Genetics research study (optional):

Exclusion criteria for participation in the optional genetics research component of the study include: a) Previous bone marrow transplant b)Nonleukocyte-depleted whole blood transfusion within 120 days of genetic sample collection.

Terms in these criteria, in plain language(27)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
102 participants (actual)

Study arms

  • Experimental
    Cohort A

    Patients received standard radiotherapy \[60 gray (Gy) ± 10% or hypofractionated BED\] prior to study entry.

    Drug: Durvalumab

  • Experimental
    Cohort B

    Patients received palliative radiotherapy \[40 to \< 54 Gy or hypofractionated BED\] prior to study entry.

    Drug: Durvalumab

Interventions

  • All patients will receive 1500 mg durvalumab via IV infusion q4w for up to a maximum of 12 months.

    Also known as: MEDI4736

06

What researchers measure

Primary outcomes

  1. Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs)

    The safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs within 6 months from the initiation of durvalumab treatment. A PRAE was any TEAE with a possible relatedness to durvalumab, or where the relatedness was missing. If relatedness of a TEAE was missing at the primary DCO (30 March 2023) the TEAE was considered a PRAE.

    Time frame: From first dose of durvalumab treatment until 6 months after initiation of durvalumab treatment

Secondary outcomes

  1. Median Progression-free Survival (mPFS)

    Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

    Time frame: From the first date of treatment until the date of objective disease progression or death or data cut-off date (36 months)

  2. Progression-free Survival at 6 Months (PFS6)

    Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

    Time frame: From the first date of treatment until the date of objective disease progression or death (6 months)

  3. Progression-free Survival at 12 Months (PFS12)

    Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

    Time frame: From the first date of treatment until the date of objective disease progression or death (12 months)

  4. Median Overall Survival (mOS)

    The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.

    Time frame: From the first date of treatment until death or data cut-off due to any cause (36 months)

  5. Overall Survival at 12 Months (OS12)

    The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.

    Time frame: From the first date of treatment until death due to any cause (12 months)

  6. Objective Response Rate (ORR)

    The ORR is the proportion (%) of patients with an overall response of complete response (CR) or partial response (PR) (confirmed by a follow-up scan at least 4 weeks after showing CR or PR) per RECIST 1.1 criteria. CR is disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \< 10 mm. PR is at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

    Time frame: From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)

  7. Duration of Response (DoR)

    The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

    Time frame: From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)

  8. Lung Cancer Mortality

    The lung cancer mortality (NSCLC-related death) is assessed using the deaths which are reported as 'NSCLC-related' and is defined as the time (days) from the date of first dose of durvalumab until date of death due to lung cancer.

    Time frame: From date of treatment start until death due to lung cancer (36 months)

  9. Number of Patients With Events (AEs)

    The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed.

    Time frame: From screening (Day -28) till data cut-off (36 months)

  10. Number of Patients With Adverse Events of Special Interests (AESIs)

    The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An AESI is an AE of scientific and medical interest specific to the understanding of durvalumab. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy. Here, number of patients experienced AESIs are presented. Serious adverse event of special interests (SAESIs).

    Time frame: From screening (Day -28) till data cut-off (36 months)

  11. Number of Patients With Immune-mediated Adverse Events (imAEs)

    The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate etiology. Here, number of patients experienced imAEs are presented. Immune-mediated serious adverse events (imSAEs)

    Time frame: From screening (Day -28) till data cut-off (36 months)

07

Results

Posted Sep 25, 2024

Participant flow

Patients were enrolled and received study treatment at 29 sites in 5 countries (France, Italy, Poland, Russian Federation, and Spain). The data in this report are based on study start date (first patient enrolled: 26 November 2020 till final analyses data cut-off date of 06 December 2023.

Participant flow — Overall Study
MilestoneDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)
Started5349
Completed5349
Not completed00

Outcome measures

PrimaryNumber of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs)

The safety and tolerability profile of durvalumab as defined by Grade 3 and Grade 4 PRAEs within 6 months from the initiation of durvalumab treatment. A PRAE was any TEAE with a possible relatedness to durvalumab, or where the relatedness was missing. If relatedness of a TEAE was missing at the primary DCO (30 March 2023) the TEAE was considered a PRAE.

Time frame:
From first dose of durvalumab treatment until 6 months after initiation of durvalumab treatment
Reported as:
Count of participants · Participants
Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs)
ParticipantsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Number of Patients With Grade 3 and Grade 4 Possibly-related Adverse Events (PRAEs)5510
SecondaryMedian Progression-free Survival (mPFS)

Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

Time frame:
From the first date of treatment until the date of objective disease progression or death or data cut-off date (36 months)
Reported as:
Median · Months
Median Progression-free Survival (mPFS)
MonthsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Median Progression-free Survival (mPFS)10.3 (7.49 to 16.56)7.6 (5.55 to 11.04)9.2 (7.39 to 11.93)
SecondaryProgression-free Survival at 6 Months (PFS6)

Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

Time frame:
From the first date of treatment until the date of objective disease progression or death (6 months)
Reported as:
Number · Percentage of patients
Progression-free Survival at 6 Months (PFS6)
Percentage of patientsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Progression-free Survival at 6 Months (PFS6)67.1 (51.96 to 78.43)59.3 (43.38 to 72.07)63.3 (52.62 to 72.25)
SecondaryProgression-free Survival at 12 Months (PFS12)

Progression-free survival is defined as the time from the date of first dose of durvalumab until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the patient discontinues durvalumab or receives another anticancer therapy prior to progression according to RECIST 1.1 as assessed by the Investigator. Patients who had not progressed or died at the time of analysis were censored at the date of their last evaluable tumor assessment. If a patient progressed or died after two or more missed visits, they were censored at the date of the latest evaluable assessment prior to the missed visits.

Time frame:
From the first date of treatment until the date of objective disease progression or death (12 months)
Reported as:
Number · Percentage of patients
Progression-free Survival at 12 Months (PFS12)
Percentage of patientsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Progression-free Survival at 12 Months (PFS12)46.8 (31.88 to 60.36)31.8 (18.13 to 46.32)39.6 (29.28 to 49.76)
SecondaryMedian Overall Survival (mOS)

The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.

Time frame:
From the first date of treatment until death or data cut-off due to any cause (36 months)
Reported as:
Median · Months
Median Overall Survival (mOS)
MonthsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Median Overall Survival (mOS)21.1 (11.60 to NA)16.8 (10.64 to NA)21.1 (14.75 to NA)
SecondaryOverall Survival at 12 Months (OS12)

The OS is defined as the time from the date of first dose of durvalumab until death due to any cause. Patients who were not known to have died at the time of analysis were censored at the last recorded date when they were known to have been alive.

Time frame:
From the first date of treatment until death due to any cause (12 months)
Reported as:
Number · Percentage of patients
Overall Survival at 12 Months (OS12)
Percentage of patientsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Overall Survival at 12 Months (OS12)64.0 (49.01 to 75.58)65.5 (49.87 to 77.26)64.7 (54.21 to 73.34)
SecondaryObjective Response Rate (ORR)

The ORR is the proportion (%) of patients with an overall response of complete response (CR) or partial response (PR) (confirmed by a follow-up scan at least 4 weeks after showing CR or PR) per RECIST 1.1 criteria. CR is disappearance of all target lesions (TLs) since baseline. Any pathological lymph nodes selected as TLs must have a reduction in short axis diameter to \< 10 mm. PR is at least a 30% decrease in the sum of the diameters of TL, taking as reference the baseline sum of diameters.

Time frame:
From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)
Reported as:
Number · Percentage of patients
Objective Response Rate (ORR)
Percentage of patientsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Objective Response Rate (ORR)34.0 (21.5 to 48.3)24.5 (13.3 to 38.9)29.4 (20.8 to 39.3)
SecondaryDuration of Response (DoR)

The DoR is defined as the time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression per RECIST1.1 or death in the absence of disease progression.

Time frame:
From 8 weeks ±1 week after durvalumab treatment initiation and continue every 8 weeks (q8w) ±1 week through 48 weeks and every 12 weeks (q12w) ±1 week until disease progression or data cut-off (36 months)
Reported as:
Median · Weeks
Duration of Response (DoR)
WeeksDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Duration of Response (DoR)56.9 (31.00 to NA)34.1 (24.29 to NA)56.9 (31.14 to NA)
SecondaryLung Cancer Mortality

The lung cancer mortality (NSCLC-related death) is assessed using the deaths which are reported as 'NSCLC-related' and is defined as the time (days) from the date of first dose of durvalumab until date of death due to lung cancer.

Time frame:
From date of treatment start until death due to lung cancer (36 months)
Reported as:
Median · Months
Lung Cancer Mortality
MonthsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Lung Cancer Mortality30.9 (16.92 to NA)NA (14.75 to NA)30.9 (16.82 to NA)
SecondaryNumber of Patients With Events (AEs)

The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed.

Time frame:
From screening (Day -28) till data cut-off (36 months)
Reported as:
Count of participants · Participants
Number of Patients With Events (AEs)
ParticipantsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Any AE504999
Any PRAE (Investigator-assessed [IA])313162
Any AE of CTCAE Grade 3 or Grade 4202141
Any AE of CTCAE Grade 3 or Grade 4, possibly related to durvalumab treatment (IA)6511
Any AE with outcome of death527
Any AE with outcome of death, possibly related to treatment (IA)101
Any SAE (including events with outcome of death)231841
Any SAE (including events with outcome of death), possibly related to treatment (IA)538
Any AE leading to discontinuation of treatment13922
Any AE leading to discontinuation of treatment, possibly related to treatment (IA)7512
Any AE leading to treatment interruption252348
Any AE leading to treatment interruption, possibly related to treatment6713
Any AESI (including events with outcome of death) (IA)252146
Any AESI (including events with outcome of death), possibly related to treatment (IA)191433
Any Adverse event of potential interest (AEPI) (including events with outcome of death) (IA)212243
Any AEPI (including events with outcome of death), possibly related to treatment (IA)141529
Any imAE (IA)272451
Any imAE, possibly related to treatment (IA)262450
SecondaryNumber of Patients With Adverse Events of Special Interests (AESIs)

The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An AESI is an AE of scientific and medical interest specific to the understanding of durvalumab. AESIs for durvalumab include, but are not limited to, events with a potential inflammatory or immune-mediated mechanism and which may require more frequent monitoring and/or interventions such as steroids, immunosuppressants and/or hormone replacement therapy. Here, number of patients experienced AESIs are presented. Serious adverse event of special interests (SAESIs).

Time frame:
From screening (Day -28) till data cut-off (36 months)
Reported as:
Count of participants · Participants
Number of Patients With Adverse Events of Special Interests (AESIs)
ParticipantsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Any AESIs252146
Any AESIs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4415
Any SAESIs [including events with outcome = death])415
Any AESIs with outcome = death101
Any AESIs, causally related to treatment191433
Any AESIs of CTCAE Grade 3 or 4, causally related to treatment415
Any SAESIs, causally related to treatment415
Any AESIs with outcome = death, causally related to treatment101
AESIs: Received systemic corticosteroids5813
AESIs: Received high dose steroids4610
AESIs: Received endocrine therapy6511
AESIs: Received other immunosuppressants000
Any AESIs leading to discontinuation of durvalumab treatment437
AESIs: Event outcome resolved131225
AESIs: Event outcome not resolved11920
SecondaryNumber of Patients With Immune-mediated Adverse Events (imAEs)

The safety and tolerability profile of durvalumab treatment, including all adverse events (AEs) was assessed. An imAE is defined as an AESI that is associated with drug exposure and is consistent with an immune-mediated mechanism of action and where there is no clear alternate etiology. Here, number of patients experienced imAEs are presented. Immune-mediated serious adverse events (imSAEs)

Time frame:
From screening (Day -28) till data cut-off (36 months)
Reported as:
Count of participants · Participants
Number of Patients With Immune-mediated Adverse Events (imAEs)
ParticipantsDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Any imAEs111526
Any imAEs of Common Terminology Criteria for Adverse Events (CTCAE) Grade 3 or 4235
Any imSAEs [including events with outcome = death])325
Any imAEs with outcome = death101
Any imAEs, causally related to treatment101222
Any imAEs of CTCAE Grade 3 or 4, causally related to treatment235
Any imSAEs, causally related to treatment325
Any imAEs with outcome = death, causally related to treatment101
imAEs: Received systemic corticosteroids71320
imAEs: Received high dose steroids5712
imAEs: Received endocrine therapy6511
imAEs: Received other immunosuppressants000
Any imAEs leading to discontinuation of durvalumab treatment347
imAEs: Event outcome resolved5813
imAEs: Event outcome not resolved5712

Adverse events

Collected over From screening (Day -28) till data cut-off (36 months). Non-serious events are listed at a 2.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Durvalumab Cohort A: Standard Radiotherapy (RT)23/53 (43.4%)23/53 (43.4%)47/53 (88.7%)
Durvaumab Cohort B: Palliative Radiotherapy (RT)23/49 (46.9%)18/49 (36.7%)45/49 (91.8%)
Durvalumab Total46/102 (45.1%)41/102 (40.2%)92/102 (90.2%)
Most frequent serious events
Showing 10 of 41
Most frequent serious events
EventDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
Cardiac failureCardiac disorders1/534/495/102
PneumoniaInfections and infestations3/532/495/102
Atrial fibrillationCardiac disorders2/530/492/102
Enterobacter sepsisInfections and infestations0/531/491/102
Pneumonia bacterialInfections and infestations0/531/491/102
Ischaemic strokeNervous system disorders0/531/491/102
SyncopeNervous system disorders0/531/491/102
Hypovolaemic shockVascular disorders0/531/491/102
Acute respiratory failureRespiratory, thoracic and mediastinal disorders0/531/491/102
AspirationRespiratory, thoracic and mediastinal disorders0/531/491/102
Most frequent other events
Showing 10 of 66
Most frequent other events
EventDurvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Durvalumab Total
AnaemiaBlood and lymphatic system disorders13/536/4919/102
AstheniaGeneral disorders13/538/4921/102
CoughRespiratory, thoracic and mediastinal disorders9/5312/4921/102
DyspnoeaRespiratory, thoracic and mediastinal disorders11/538/4919/102
ConstipationGastrointestinal disorders3/5310/4913/102
FatigueGeneral disorders1/5310/4911/102
HypothyroidismEndocrine disorders9/536/4915/102
PruritusSkin and subcutaneous tissue disorders5/538/4913/102
PyrexiaGeneral disorders8/538/4916/102
Decreased appetiteMetabolism and nutrition disorders8/536/4914/102

Baseline characteristics

The safety analysis set consisted of all patients who received at least one dose of durvalumab treatment.

Age, Continuous
Age, Continuous(Years)Durvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Total
Mean74.7 ± 9.1878.8 ± 6.7176.7 ± 8.32
Sex: Female, Male
Sex: Female, Male(Participants)Durvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Total
Female151429
Male383573
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Total
White464591
Other101
Unknown314
Missing336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Durvalumab Cohort A: Standard Radiotherapy (RT)Durvaumab Cohort B: Palliative Radiotherapy (RT)Total
Hispanic or Latino235
Not Hispanic or Latino454388
Missing639
08

Study locations

35 sites
  • Research Site
    Tucson, Arizona 85704, United States
  • Research Site
    Tampa, Florida 33612, United States
  • Research Site
    Royal Oak, Michigan 48073, United States
  • Research Site
    Limoges, 87000, France
  • Research Site
    Marseille, 13009, France
  • Research Site
    Montpellier, 34070, France
  • Research Site
    Nimes, 30029, France
  • Research Site
    Rouen, 76031, France
  • Research Site
    Brescia, 25100, Italy
  • Research Site
    Firenze, 50134, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Meldola, 47014, Italy
  • Research Site
    Messina, 98158, Italy
  • Research Site
    Modena, 41124, Italy
  • Research Site
    Monza, 20900, Italy
  • Research Site
    Negrar, 37024, Italy
  • Research Site
    Pavia, 27100, Italy
  • Research Site
    Pisa, 56124, Italy
  • Research Site
    Ravenna, 48121, Italy
  • Research Site
    Roma, 00128, Italy
  • Research Site
    Białystok, 15-044, Poland
  • Research Site
    Gdańsk, 80-214, Poland
  • Research Site
    Olsztyn, 10-228, Poland
  • Research Site
    Szczecin, 71-730, Poland
  • Research Site
    Warszawa, 02-781, Poland
  • Research Site
    St. Petersburg, 197002, Russian Federation
  • Research Site
    St. Petersburg, 197758, Russian Federation
  • Research Site
    Ufa, 450054, Russian Federation
  • Research Site
    A Coruña, 15006, Spain
  • Research Site
    Barcelona, 8035, Spain
  • Research Site
    Castello de la Plana, 12002, Spain
  • Research Site
    Madrid, 28050, Spain
  • Research Site
    Oviedo, 33011, Spain
  • Research Site
    Pamplona, 31008, Spain
  • Research Site
    Sabadell(Barcelona), 08208, Spain
09

References and documents

Publications

  • Filippi AR, Dziadziuszko R, Garcia Campelo MR, Paoli JB, Sawyer W, Diaz Perez IE. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy. Future Oncol. 2021 Dec;17(34):4657-4663. doi: 10.2217/fon-2021-0952. Epub 2021 Nov 15. PubMed 34775804 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2020 to primary completion in Mar 2023, 28 months.

Results were first posted in Sep 2024, 1 year 5 months after primary completion. A results delay was requested in Feb 2024.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 28 months is below that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Jan 30, 2020
StartActual
Nov 26, 2020
Primary completionActual
Mar 30, 2023
CompletionActual
Nov 25, 2024
Results delay requested
Feb 23, 2024
Results first posted
Sep 25, 2024
Last update
Jan 10, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04249362
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jan 30, 2020
Start date
Nov 26, 2020
Primary completion
Mar 30, 2023
Completion
Nov 25, 2024
Results posted
Sep 25, 2024
Last update
Jan 10, 2025

Study contacts

Dr Andrea Riccardo Filippi
principal investigator · Fondazione IRCCS Policlinico San Matteo

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Durvalumab

Start the discussion